Insulin-like action of novel metformin-containing vanadate as a new antidiabatic drug: Synthesis, characterization and crystal structure of [Metformin-H]2[V2O6] ]·H2O

• A new combination of metformin as a substitute for insulin therapy and vanadate [Met-H]2[V2O6]·H2O 1.
• The crystal structure of 1 shows that each vanadium atom, has a distorted tetrahedral {VO4} environment.
• The glucose lowering activity by oral administration of 1 in streptozotocin-induced diabetic rats was examined.

A new vanadate compound, which contains interlamellary, the insulin enhancing agent metformin was prepared. Its structure was established to be [Metformin]2[V2O6]·H2O 1 by using elemental analysis, FT-IR and 1H–13C NMR spectroscopic methods. The crystal structure of 1 shows that each of the two vanadium atoms is coordinated to four oxygen atoms, forming a distorted tetrahedral {VO4} that are arranged alternately to form one-dimension {V2O6}n2n−{V2O6}n2n− chains. The chains are stabilized by an extensive hydrogen bonding involving oxide ligands of the chains and metformin molecules which fill the space between the stacks of chains. Furthermore, powder X-ray diffraction, EDX-SEM and TGA-DTA analysis of compound 1 are also investigated, which demonstrates its high purity and thermal stability. The thermoanalytical data evidence that compound 1 undergo complete decomposition, resulting in V2O5 as a residual product. Investigation of the glucose lowering activity by oral administration of compound 1 in streptozotocin-induced diabetic rats was examined.

A new combination of metformin as a substitute for insulin therapy and vanadate namely, [Met-H]2[V2O6] ]·H2O 1 was synthesized and structurally characterized Investigation of the glucose lowering activity by oral administration of compound 1 in Streptozotocin-induced diabetic Rats was examined.Figure optionsDownload as PowerPoint slide